Suzhou Maoxing Biotechnology

Suzhou Maoxing Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of universal CAR-T (UCART) therapies for solid tumors. The company leverages advanced CRISPR/Cas9 gene editing and non-viral delivery systems to create "off-the-shelf" cell products that aim to overcome the limitations of traditional autologous treatments. Its lead candidate, MT027, is an allogeneic CAR-T therapy targeting B7-H3 for the treatment of recurrent glioblastoma, which has received IND clearance from both the FDA and NMPA. Maoxing Biotech is focused on expanding its pipeline to address various high-unmet-need oncological indications through its proprietary cell engineering platforms. By industrializing cell therapy, the company seeks to significantly reduce costs and improve patient accessibility to life-saving immunotherapies.